A single-center, single-dose, randomized, three-way crossover phase I study comparing pharmacokinetics, safety and tolerability of two formulations of AP-CBD/THC, with Buccal Sativex in healthy volunteers

Trial Profile

A single-center, single-dose, randomized, three-way crossover phase I study comparing pharmacokinetics, safety and tolerability of two formulations of AP-CBD/THC, with Buccal Sativex in healthy volunteers

Completed
Phase of Trial: Phase I

Latest Information Update: 09 Aug 2017

At a glance

  • Drugs Cannabidiol/tetrahydrocannabivarin-9 (Primary) ; Nabiximols
  • Indications Pain
  • Focus Adverse reactions
  • Most Recent Events

    • 09 Aug 2017 Status changed from recruiting to completed, according to an Intec Pharma media release.
    • 03 Aug 2017 Results published in an Intec Pharma media release.
    • 22 Mar 2017 According to an Intec Pharma media release, topline results from this trial are expected in the third quarter of 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top